Figure 7.

EP₂ agonist exposure results in a marked increase in invasiveness in vector control clones. A: Three vector control clones were treated with vehicle, and 1 ng/ml, 100 ng/ml, and 1000 ng/ml of 11d-PGE₁ for 3 days before plating on dermal equivalents, and every other day thereafter. Skin equivalents were grown for 8 days submerged in growth media and for 3 days at the air-liquid interface. Results represent the mean and SE for depth of invasion into the dermal compartment (*, P < 0.05). B: Similar results for two vector control clones treated with vehicle, and 100 ng/ml and 1000 ng/ml butaprost.